How to Improve Access to CAR T-cell Therapy: The Role of Policy and Innovation

In this ONCOLife exclusive, Dr. John Gribben, Professor at the Cancer Institute in London, offers a compelling look into the evolving clinical and systemic landscape of CAR T-cell therapy—a breakthrough bringing new hope to patients with aggressive blood cancers. Dr. Gribben shares expert insights on the barriers limiting patient access, and what needs to change to ensure more eligible patients can benefit from this life-saving treatment. You can also follow this interview on LinkedIn using this link:>>>

He underscores the urgency of aligning clinical practice with policy reform, the role of real-world data in shaping health technology assessments, and the critical steps needed to expand treatment capacity as CAR T indications grow. We also explore the bold mission of the CAR T Vision initiative: to double access to CAR T-cell therapy by 2030—and what healthcare systems must do now to make that vision a reality.

Some of the main topics in this interview include:

✔️ The current state and future potential of CAR T-cell therapy in oncology
✔️ Key systemic barriers limiting access to treatment
✔️ The role of policy, innovation, and real-world evidence in expanding access
✔️ How to prepare health systems for broader use of CAR T-cell therapy
✔️ The strategic vision to double CAR T-cell access by 2030